Company profile: xCella Biosciences
1.1 - Company Overview
Company description
- Provider of antibody discovery technologies, offering a platform to screen single B cells and develop therapeutics via protein engineering. Products include the OmniAb Discovery Platform and transgenic animal systems: OmniRat, OmniMouse, OmniChicken for generating fully human antibodies; OmniFlic and OmniClic for bispecific discovery; and xPloration integrated hardware/software for high-dimensional measurement and analysis.
Products and services
- OmniAb Discovery Platform: Delivers a suite of transgenic animal technologies that generate human antibodies, facilitating development of human therapeutic candidates
- OmniChicken: Architects a transgenic chicken platform generating human-sequence antibodies, ideal for discovering antibodies to conserved mammalian targets
- OmniFlic: Builds a transgenic rat platform designed for bispecific antibody applications using a common light chain approach
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to xCella Biosciences
ImmunoGenesis
HQ: United States
Website
- Description: Provider of immune therapies for tumor treatment, including IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor with cytotoxic effector function for immune-excluded tumors resistant to immunotherapies; IMGS-501, an antibody-conjugated STING agonist delivered via PD-L1/PD-L2 targeting to tumor sites; and IMGS-101, a hypoxia-reversal agent that reoxygenates the tumor microenvironment to enable T-cell access.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGenesis company profile →
Selexys Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexys Pharmaceuticals company profile →
Argenx
HQ: United States
Website
- Description: Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argenx company profile →
Themis Bioscience
HQ: Austria
Website
- Description: Provider of vaccine R&D focused on preventing infectious diseases. The start-up biotechnology company concentrates on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Themis Bioscience company profile →
Morphotek
HQ: United States
Website
- Description: Provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphotek company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for xCella Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to xCella Biosciences
2.2 - Growth funds investing in similar companies to xCella Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for xCella Biosciences
4.2 - Public trading comparable groups for xCella Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →